These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23726024)

  • 21. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
    Chatenoud L; Waldmann H
    Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune therapy and β-cell death in type 1 diabetes.
    Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
    Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
    Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
    Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
    Chatenoud L
    Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L
    Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review.
    LeFevre JD; Cyriac SL; Tokmic A; Pitlick JM
    Am J Health Syst Pharm; 2022 Nov; 79(23):2099-2117. PubMed ID: 36056809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers for immune intervention trials in type 1 diabetes.
    Mallone R; Roep BO
    Clin Immunol; 2013 Dec; 149(3):286-96. PubMed ID: 23510725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
    Bach JF
    Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
    [No Abstract]   [Full Text] [Related]  

  • 30. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
    N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
    Herold KC; Gitelman SE; Masharani U; Hagopian W; Bisikirska B; Donaldson D; Rother K; Diamond B; Harlan DM; Bluestone JA
    Diabetes; 2005 Jun; 54(6):1763-9. PubMed ID: 15919798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
    Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
    Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD3-specific antibodies: a portal to the treatment of autoimmunity.
    Chatenoud L; Bluestone JA
    Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DiaPep277® and immune intervention for treatment of type 1 diabetes.
    Schloot NC; Cohen IR
    Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
    Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.
    Bisikirska BC; Herold KC
    Ann N Y Acad Sci; 2004 Dec; 1037():1-9. PubMed ID: 15699486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical studies. Trying to reset the clock on type 1 diabetes.
    Couzin-Frankel J
    Science; 2011 Aug; 333(6044):819-21. PubMed ID: 21835995
    [No Abstract]   [Full Text] [Related]  

  • 39. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
    Hagopian W; Ferry RJ; Sherry N; Carlin D; Bonvini E; Johnson S; Stein KE; Koenig S; Daifotis AG; Herold KC; Ludvigsson J;
    Diabetes; 2013 Nov; 62(11):3901-8. PubMed ID: 23801579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis.
    Liu Y; Li W; Chen Y; Wang X
    Endocrine; 2024 Feb; 83(2):322-329. PubMed ID: 37658243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.